2.4.0.8119 - Disclosure - Organization and Business - Additional Information (Detail)truefalsefalse1false USDfalsefalse$P07_01_2012To07_31_2012http://www.sec.gov/CIK0001133818duration2012-07-01T00:00:002012-07-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P04_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$P01_01_2012To06_30_2012http://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$P01_01_2011To12_31_2011http://www.sec.gov/CIK0001133818duration2011-01-01T00:00:002011-12-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDfalsefalse$P05_10_2007To06_30_2013http://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDfalsefalse$PAsOn05_09_2007http://www.sec.gov/CIK0001133818instant2007-05-09T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3bpth_OrganizationAndNatureOfOperationsLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization and Nature of Operations [Line Items]2false 4bpth_PercentageOfChangeInDepreciationAmortizationOfIntangibleAssetsAndAssetImpairmentAndOtherChargesOperatingbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truetruefalse0.50.5falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsenum:percentItemTypepurePercentage of Change in Depreciation Amortization of Intangible Assets and Asset Impairment and Other Charges OperatingNo definition available.false0Percentage of Charge3false 4us-gaap_OtherAssetImpairmentChargesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00USD$falsetruefalse4truefalsefalse345000345000USD$falsetruefalse5truefalsefalse345000345000USD$falsetruefalse6truefalsefalse690000690000USD$falsetruefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230 false2Impairment of License4false 4us-gaap_Cashus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse19272261927226USD$falsefalsefalse3truefalsefalse19272261927226USD$falsefalsefalse4truefalsefalse162440162440USD$falsefalsefalse5truefalsefalse952252952252USD$falsefalsefalse6truefalsefalse19272261927226USD$falsefalsefalse7truefalsefalse534046534046USD$falsefalsefalse8truefalsefalse00USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Cash5false 4bpth_OtherAssetImpairmentChargesSirnaLicensebpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse345000345000USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryOther Asset Impairment Charges Sirna LicenseNo definition available.false2Carrying value of the siRNA license6false 4us-gaap_ProceedsFromIssuanceOfPrivatePlacementus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse40000004000000USD$falsefalsefalse2truefalsefalse25000002500000USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from issuance of private placement7false 4bpth_ProceedsFromIssuanceOfPrivatePlacementTwobpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse40000004000000USD$falsetruefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryProceeds form issuance of private placement two.No definition available.false2Proceeds form additional issuance of private placement8false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9false truefalsePAsOn06_30_2013_PhaseOneMemberusgaapProductOrServiceAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalsePhase I clinical trialus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PhaseOneMemberus-gaap_ProductOrServiceAxisexplicitMemberNumberStandardhttp://www.biopathholdings.com/20130630Numberbpth0nanafalse0Phase I clinical trial9true 3bpth_OrganizationAndNatureOfOperationsLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization and Nature of Operations [Line Items]10false 4bpth_NumberOfPatientsbpth_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse33falsefalsefalse3truefalsefalse33falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse33falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerNumber of PatientsNo definition available.false256Number patients benefited from Liposomal Grb-2 treatmentfalseOrganization and Business - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/OrganizationAndBusinessAdditionalInformationDetail810